Influence of Medication Taste on Pediatric Prescribers' Prescribing Habits

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Bernard Lee, Mayo Clinic

ClinicalTrials.gov Identifier:

NCT01734759

First received: November 17, 2012

Last updated: October 18, 2013

Last verified: October 2013

History of Changes

Purpose

The purpose of this study is to see if a medication taste test influences the prescribing habits of pediatric prescribers at Mayo Clinic.

Condition	Intervention	Phase
Healthy	Drug: Taste Test	Phase 1


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Health Services Research
Official Title:	Influence of Medication Palatability on Prescribing Habits of Pediatric Prescribers

Resource links provided by NLM:

MedlinePlus related topics: Taste and Smell Disorders

U.S. FDA Resources

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:

Taste scores on the visual analog scale [ Time Frame: Change from baseline in taste scores at 3 months ] [ Designated as safety issue: No ]
Medication taste scores on the visual analog scale before and after a medication tasting will be measured.


Enrollment:	50
Study Start Date:	November 2012
Study Completion Date:	January 2013
Primary Completion Date:	January 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Taste Test	Drug: Taste Test Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested. Medications to be sampled and the corresponding dose of the test dose are: Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg Steroids: prednisolone 1.5 mg, prednisone 0.5 mg H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg

Arms

Assigned Interventions

Experimental: Taste Test

Drug: Taste Test

Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.

Medications to be sampled and the corresponding dose of the test dose are:

Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg
Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg
Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg
Steroids: prednisolone 1.5 mg, prednisone 0.5 mg
H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

subjects possess prescriptive authority (e.g. MD, nurse practitioner, physician's assistant, medication therapy management pharmacists)
subjects have prescribed at least one of the study medications from one of the medication classes to pediatric patients at an outpatient clinic in the three months preceding the study

Exclusion Criteria:

subjects do not prescribe any of the tested medications
subject has an allergy to all of the study medications
subject is pregnant or breastfeeding
subject has a medical condition that prevents them from being involved in the taste test

Participants are advised to be within or accessible to the Rochester, MN area during study recruitment and accessible afterwards via mail, email or fax.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01734759

Locations


United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905

Sponsors and Collaborators

Mayo Clinic

Investigators


Principal Investigator:	Bernard Lee, PharmD, RPh	Mayo Clinic
Principal Investigator:	Ole J Olson, Pharm.D., BCPS	Mayo Clinic
Study Director:	Michelle J LoTurco, Pharm.D.	Mayo Clinic

More Information


Responsible Party:	Bernard Lee, Principle Investigator, Mayo Clinic
ClinicalTrials.gov Identifier:	NCT01734759 History of Changes
Other Study ID Numbers:	12-005823
Study First Received:	November 17, 2012
Last Updated:	October 18, 2013
Health Authority:	United States: Institutional Review Board

Keywords provided by Mayo Clinic:


medication palatability medication taste

ClinicalTrials.gov processed this record on September 23, 2016

To Top